Investigational drug · Phase 3
Ifebemtinib
Also called: IN10018, BI853520
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, NSCLC, Solid Tumor Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
11 still active
All registered trials
2
Any phase or sponsor naming "Ifebemtinib"
First trial start
2020
Jul 27, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ifebemtinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
- NSCLC
- Solid Tumor Cancer
- PDAC
- Pancreatic Cancer
- Ovarian Cancer Recurrent
- Platinum-resistant Ovarian Cancer
- Biliary Tract Cancer
- Melanoma
- Small Cell Lung Cancer Extensive Stage
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Ifebemtinib" as an intervention, largest first.
- a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid TumorsPivotal-lookingActive, not recruiting
InxMed (Shanghai) Co., Ltd.Industry
NCT06166836 · 140 participants (planned) · Start Oct 12, 2022 · Primary completion Dec 31, 2027
Drug: D1553; IN10018(Ifebemtinib) · For: Solid Tumor
Sites: Hangzhou, China; Bengbu, China; Changsha, China · 10 sites in all
Capital Medical UniversityAcademic, hospital or other
NCT07652762 · 24 participants (planned) · Start Aug 31, 2026 · Primary completion Aug 2028
Drug: Ifebemtinib; Dalpiciclib · For: Meningioma; CDK4/6 Inhibitor
Sites: Beijing, China · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Tumor FAK supports fibrillar collagen expression in ovarian cancer ascites.
Ojalill M, Haanen TJ, Khan SU, et al. · Matrix Biol 2026
- Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial.
Song Z, Zhu L, Liu Y, et al. · Lancet Oncol 2026
- Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial.
Song Z, Li X, Lin R, et al. · Lancet Respir Med 2026
- Inhibition of Focal Adhesion Restricts Chemoresistance in Pancreatic Cancer by Targeting SLC7A11 Mediated Ferroptosis.
Wang Y, Yang H, Zhang B, et al. · Adv Sci (Weinh) 2026
- Focal adhesion kinase inhibition enhances response to checkpoint immunotherapy in hepatocellular carcinoma.
Liu X, Wang F, Cui P, et al. · J Transl Int Med 2026
- Ifebemtinib and paclitaxel synergistically inhibit the proliferation and metastasis of TNBC by blocking PI3K/Akt pathway through LSD1/PIK3IP1 axis.
Li Y, Li L, Mao Q, et al. · Sci Rep 2025
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- ZG006Phase 38 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.